Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

15.79 -0.25 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,596
Open 16.04
Bid (Size) 12.92 (1)
Ask (Size) 16.24 (2)
Prev. Close 16.04
Today's Range 15.02 - 16.15
52wk Range 5.005 - 18.70
Shares Outstanding 101,102,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
Via Benzinga

Performance

YTD
+11.5%
+11.5%
1 Month
+28.4%
+28.4%
3 Month
+21.3%
+21.3%
6 Month
+134.3%
+134.3%
1 Year
+70.3%
+70.3%

More News

Read More
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Pricing of $16 Million Offering
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
Via Benzinga
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
From Atara Biotherapeutics, Inc.
Via Business Wire
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates
Via Benzinga
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip
Via Stocktwits
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
Via Benzinga
US Stocks Edge Lower; Retail Sales Increase Less Than Expected
Via Benzinga
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
The current price of Atara Biotherapeutics, Inc. - Common Stock is 15.79
When was Atara Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 10/21/25 04:00 PM ET
What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 1.60B
How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
Atara Biotherapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.